Sinopharm
Establishment time : 1998
website : www.sinopharm.com
Main Product : Pharmaceuticals, medical devices, healthcare services
Company Profile
Sinopharm Group Co., Ltd. is a leading pharmaceutical and healthcare company in China, with a wide range of products and services catering to the healthcare needs of millions of people. Established in 1998, Sinopharm has grown to become a major player in the global pharmaceutical industry, with a strong presence in markets across Asia, Africa, and the Middle East. With a focus on innovation and quality, Sinopharm continues to expand its product portfolio and market reach, solidifying its position as a key player in the healthcare sector.
Changchun Zhuoyi Biological Co., Ltd
Company Profile
Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.
CanSino Biologics
Establishment time : August 2009
website : www.cansinotech.com
Main Product : COVID-19 vaccine, Convidecia
Company Profile
CanSino Biologics is a biopharmaceutical company specializing in the research, development, and production of vaccines. Established in 2009, the company has gained recognition for its COVID-19 vaccine, Convidecia, which has been approved for emergency use in several countries. With a focus on innovation and collaboration, CanSino Biologics continues to make strides in the field of vaccine development.
Beijing Wantai Biological Pharmacy
Establishment time : 1998
website : www.bjwtyy.com
Main Product : Diagnostic test kits for infectious diseases
Company Profile
Beijing Wantai Biological Pharmacy is a leading provider of diagnostic test kits for infectious diseases. Established in 1998, the company has a strong presence in the Chinese market and has expanded its reach to other regions such as Asia, Africa, and Latin America. With a focus on quality and innovation, Wantai continues to be a key player in the field of biopharmaceuticals.
Clover Biopharmaceuticals
Establishment time : Clover Biopharmaceuticals is a biotechnology company focused on developing novel biologic therapies and vaccines.
website :
Main Product : Clover's main product is its COVID-19 vaccine, which has shown promising results in clinical trials.
Company Profile
With a dedicated team of scientists and researchers, Clover is poised to make a significant impact in the biopharmaceutical industry.
June 03, 2024
